| SCHEDULE OF SEGMENT INFORMATION |
SCHEDULE OF SEGMENT INFORMATION
| |
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
| |
|
For
the Three Months Ended
July 31, |
|
|
For
the Nine Months Ended
July 31, |
|
| |
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
| Net
loss: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cancer
Vaccines |
|
$ |
(1,298 |
) |
|
$ |
(2,160 |
) |
|
$ |
(5,195 |
) |
|
$ |
(5,628 |
) |
| CAR-T
Therapeutics |
|
|
(973 |
) |
|
|
(1,145 |
) |
|
|
(3,074 |
) |
|
|
(4,115 |
) |
| Other |
|
|
(9 |
) |
|
|
(10 |
) |
|
|
(37 |
) |
|
|
(42 |
) |
| Total |
|
$ |
(2,280 |
) |
|
$ |
(3,315 |
) |
|
$ |
(8,306 |
) |
|
$ |
(9,785 |
) |
| Net
loss |
|
$ |
(2,280 |
) |
|
$ |
(3,315 |
) |
|
$ |
(8,306 |
) |
|
$ |
(9,785 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Total
operating costs and expenses |
|
$ |
2,436 |
|
|
$ |
3,592 |
|
|
$ |
8,825 |
|
|
$ |
10,668 |
|
| Less
non-cash stock-based compensation |
|
|
(855 |
) |
|
|
(1,179 |
) |
|
|
(2,899 |
) |
|
|
(3,699 |
) |
| Operating
costs and expenses excluding non-cash stock-based compensation |
|
$ |
1,581 |
|
|
$ |
2,413 |
|
|
$ |
5,926 |
|
|
$ |
6,969 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Operating
costs and expenses excluding non-cash stock-based compensation: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cancer
Vaccines |
|
$ |
884 |
|
|
$ |
1,614 |
|
|
$ |
3,714 |
|
|
$ |
3,988 |
|
| CAR-T
Therapeutics |
|
|
689 |
|
|
|
789 |
|
|
|
2,180 |
|
|
|
2,943 |
|
| Other |
|
|
8 |
|
|
|
10 |
|
|
|
32 |
|
|
|
38 |
|
| Total |
|
$ |
1,581 |
|
|
$ |
2,413 |
|
|
$ |
5,926 |
|
|
$ |
6,969 |
|
| Operating costs and expenses excluding non-cash stock-based compensation |
|
$ |
1,581 |
|
|
$ |
2,413 |
|
|
$ |
5,926 |
|
|
$ |
6,969 |
|
| |
|
July
31,
2025 |
|
|
October
31,
2024 |
|
| Total
assets: |
|
|
|
|
|
|
|
|
| Cancer
Vaccines |
|
$ |
9,842 |
|
|
$ |
12,917 |
|
| CAR-T
Therapeutics |
|
|
7,691 |
|
|
|
8,535 |
|
| Other |
|
|
118 |
|
|
|
139 |
|
| Total |
|
$ |
17,651 |
|
|
$ |
21,591 |
|
| Total assets |
|
$ |
17,651 |
|
|
$ |
21,591 |
|
|